0 190

Cited 6 times in

BCL2-like 11 intron 2 deletion polymorphism is not associated with non-small cell lung cancer risk and prognosis

 Eun Na Cho  ;  Eun Young Kim  ;  Ji Ye Jung  ;  Arum Kim  ;  In Jae Oh  ;  Young Chul Kim  ;  Yoon Soo Chang 
 LUNG CANCER, Vol.90(1) : 106-110, 2015 
Journal Title
Issue Date
Aged ; Apoptosis Regulatory Proteins/genetics* ; Base Sequence ; Bcl-2-Like Protein 11 ; Carcinoma, Non-Small-Cell Lung/genetics* ; Carcinoma, Non-Small-Cell Lung/pathology ; Disease-Free Survival ; Female ; Gene Deletion ; Humans ; Introns* ; Lung Neoplasms/genetics* ; Lung Neoplasms/pathology ; Male ; Membrane Proteins/genetics* ; Middle Aged ; Molecular Sequence Data ; Polymorphism, Genetic ; Prognosis ; Prospective Studies ; Proto-Oncogene Proteins/genetics* ; Receptor, Epidermal Growth Factor/genetics ; Risk Factors ; Sequence Deletion* ; Smoking/genetics ; Smoking/pathology ; Survival Analysis
BIM intron 2 deletion polymorphism ; Non-small cell lung cancer ; Prognosis ; Risk factors ; bcl-2-like 11
OBJECTIVES: BCL2-Like 11(BIM), which encodes a BH3-only protein, is a major pro-apoptotic molecule that facilitates cell death. We hypothesized that a BIM intron 2 deletion polymorphism increases lung cancer risk and predicts poor prognosis in non-small lung cancer (NSCLC) patients. MATERIALS AND METHODS: We prospectively recruited 450 lung cancer patients and 1:1 age, sex, and smoking status matched control subjects from February 2013 to April 2014 among patients treated at Severance, Gangnam Severance, and Chonnam Hwasoon Hospital. The presence of a 2903-bp genomic DNA deletion polymorphism of intron 2 of BIM was analyzed by PCR and validated by sequencing. Odds ratios were calculated by chi-square tests and survival analysis with Kaplan-Meier estimation. RESULTS AND CONCLUSION: Sixty-nine out of 450 (15.3%) lung cancer patients carried the BIM deletion polymorphism, while 66 out of 450 (14.7%) control subjects carried the BIM deletion polymorphism, with an odds ratio of for lung cancer of 1.054 (95% CI; 0.731-1.519). We categorized 406 NSCLC patients according to the presence of the polymorphism and found that there were no statistically significant differences in age, sex, histologic type, or stage between subjects with and without the deletion polymorphism. The BIM deletion polymorphism did not influence overall survival (OS) or progression free survival (PFS) in our sample (OS; 37.6 vs 34.4 months (P=0.759), PFS; 49.6 vs 26.0 months (P=0.434)). These findings indicate that the BIM deletion polymorphism is common in Korean NSCLC patients but does not significantly affect the intrinsic biologic function of BH3-only protein. Furthermore, the BIM deletion polymorphism did not predict clinical outcomes in patients with NSCLC.
Full Text
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Yonsei Biomedical Research Center (연세의생명연구원) > 1. Journal Papers
Yonsei Authors
Kim, A Rum(김아름)
Kim, Eun Young(김은영) ORCID logo https://orcid.org/0000-0002-3281-5744
Chang, Yoon Soo(장윤수) ORCID logo https://orcid.org/0000-0003-3340-4223
Jung, Ji Ye(정지예) ORCID logo https://orcid.org/0000-0003-1589-4142
Cho, Eun Na(조은나)
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.